Early research (Phase 1)Looking for participantsNCT07224373What this trial is testingAn Open-label Study of AZD0120 in Adults With Multiple SclerosisWho this might be right forMultiple Sclerosis AstraZeneca 24
Post-approval studies (Phase 4)Study completedNCT03784898What this trial is testingCollection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving LemtradaWho this might be right forMultiple Sclerosis Genzyme, a Sanofi Company 13
Not applicableLooking for participantsNCT07353216What this trial is testingExploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) LevelsWho this might be right forMultiple Sclerosis Third Affiliated Hospital, Sun Yat-Sen University 80
Large-scale testing (Phase 3)Active Not RecruitingNCT04130997What this trial is testingAn Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisWho this might be right forRelapsing Multiple Sclerosis (RMS) TG Therapeutics, Inc. 1,100
Not applicableStudy completedNCT06251986What this trial is testingA Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical PracticeWho this might be right forRelapsing Forms of Multiple Sclerosis Novartis Pharmaceuticals 310
Not applicableLooking for participantsNCT06486779What this trial is testingKesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational StudyWho this might be right forRelapsing Multiple Sclerosis (RMS) Novartis Pharmaceuticals 160
Large-scale testing (Phase 3)Active Not RecruitingNCT06847724What this trial is testingComparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisWho this might be right forRelapsing Multiple Sclerosis Sandoz 183
Not applicableStudy completedNCT01601119What this trial is testingImpact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) PatientsWho this might be right forRelapsing Multiple Sclerosis Merck KGaA, Darmstadt, Germany 545
Not applicableStudy completedNCT05266469What this trial is testingExploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the GulfWho this might be right forRelapsing Multiple Sclerosis Novartis Pharmaceuticals 168
Large-scale testing (Phase 3)Ended earlyNCT04338022What this trial is testingStudy of Evobrutinib in Participants With RMS (evolutionRMS 1)Who this might be right forRelapsing Multiple Sclerosis Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 1,124
Early research (Phase 1)Study completedNCT01585766What this trial is testingSafety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis, Relapsing Forms MedImmune LLC 56
Testing effectiveness (Phase 2)Looking for participantsNCT07161258What this trial is testingA Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)Who this might be right forRelapsing Multiple Sclerosis Hoffmann-La Roche 12
Not applicableLooking for participantsNCT06433752What this trial is testingA Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)Who this might be right forRelapsing Multiple SclerosisMultiple Sclerosis TG Therapeutics, Inc. 2,000
Large-scale testing (Phase 3)Study completedNCT02576717What this trial is testingA Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisWho this might be right forMultiple Sclerosis Celgene 2,494
Post-approval studies (Phase 4)Study completedNCT03257358What this trial is testingImmune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg FingolimodWho this might be right forRelapsing Multiple Sclerosis Novartis Pharmaceuticals 382
Large-scale testing (Phase 3)Study completedNCT02294058What this trial is testingStudy of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)Who this might be right forMultiple Sclerosis Celgene 1,346
Post-approval studies (Phase 4)Study completedNCT04377555What this trial is testingProspective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabWho this might be right forMultiple Sclerosis, Relapsing Genentech, Inc. 179
Large-scale testing (Phase 3)Study completedNCT04486716What this trial is testingA Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple SclerosisWho this might be right forRelapsing Multiple Sclerosis Novartis Pharmaceuticals 111
Large-scale testing (Phase 3)Study completedNCT05083923What this trial is testingDiroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)Who this might be right forRelapsing Forms of Multiple Sclerosis Biogen 136
Not applicableStudy completedNCT01128075What this trial is testingTreatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis SubjectsWho this might be right forMultiple SclerosisMS Merck KGaA, Darmstadt, Germany 198